Litigation Details for PFIZER INC. v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2020)
✉ Email this page to a colleague
PFIZER INC. v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2020)
| Docket | ⤷ Subscribe | Date Filed | 2020-02-28 |
| Court | District Court, D. New Jersey | Date Terminated | 2020-06-05 |
| Cause | 35:271 Patent Infringement | Assigned To | Freda L. Wolfson |
| Jury Demand | None | Referred To | Zahid Nisar Quraishi |
| Patents | 6,956,041; 6,965,027; 7,091,208; 7,265,221; 7,301,023; 7,842,699; RE41,783 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in PFIZER INC. v. ZYDUS PHARMACEUTICALS (USA) INC.
The small molecule drugs covered by the patents cited in this case are ⤷ Subscribe and ⤷ Subscribe .
Biologic Drugs cited in PFIZER INC. v. ZYDUS PHARMACEUTICALS (USA) INC.
The biologic drug covered by the patents cited in this case is ⤷ Subscribe .
Details for PFIZER INC. v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-02-27 | 1 | four additional patents for Xeljanz that are not at issue: U.S. Patent Nos. 6,956,041 (expiring December…infringement of United States Patent No. 6,965,027 (“the ’027 patent”), United States Patent No. 7,301,023 (“the…the ’023 patent”), and United States Reissue Patent No. RE41,783 (“the RE’783 patent”). 9. … the ’027 patent as March 25, 2023, the ’023 patent as May 23, 2022, and the RE’783 patent as December… valid claim of [the RE’783 patent, the ’027 patent, and the ’023 patent] will be infringed by the manufacture | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
